Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Long-Term Investments (2025 - 2026)

Maze Therapeutics' Long-Term Investments history spans 2 years, with the latest figure at $10.6 million for Q1 2026.

  • On a quarterly basis, Long-Term Investments changed N/A to $10.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $10.6 million, a N/A change, with the full-year FY2025 number at $18.1 million, changed N/A from a year prior.
  • Long-Term Investments hit $10.6 million in Q1 2026 for Maze Therapeutics, down from $18.1 million in the prior quarter.
  • Over the last five years, Long-Term Investments for MAZE hit a ceiling of $18.1 million in Q4 2025 and a floor of $10.6 million in Q1 2026.